Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Electrocardiography as an early cardiac screening test in children with mitochondrial disease

  • Baik, Ran (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Chae, Jung-Hyun (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Lee, Young-Mock (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Kang, Hoon-Chul (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Lee, Joon-Soo (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Kim, Heung-Dong (Department of Pediatrics, Yonsei University College of Medicine)
  • 투고 : 2009.09.14
  • 심사 : 2009.10.20
  • 발행 : 2010.05.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: To evaluate myocardial conductivity to understand cardiac involvement in patients with mitochondrial disease. Methods: We performed retrospective study on fifty-seven nonspecific mitochondrial encephalopathy patients with no clinical cardiac manifestations. The patients were diagnosed with mitochondrial respiratory chain complex defects through biochemical enzyme assays of muscle tissue. We performed standard 12-lead electrocardiography (ECG) on all patients. Results: ECG abnormalities were observed in 30 patients (52.6%). Prolongation of the QTc interval (>440 ms) was seen in 19 patients (33.3%), widening of the corrected QRS interval in 15 (26.3%), and bundle branch block in four (7.0%). Atrioventricular block, premature atrial contraction and premature ventricular contraction were seen in two patients each (3.5%) and Wolff-Parkinson-White syndrome in one patient (1.8%). Conclusion: Given this finding, we recommend active screening with ECG in patients with mitochondrial disease even in patients without obvious cardiac manifestation.

키워드

참고문헌

  1. MacFarland R, Taylor RW, Turnbull DM. Mitochondrial diseases-its impact, etiology, and pathology. Curr Top Dev Biol 2007;77:113-55. https://doi.org/10.1016/S0070-2153(06)77005-3
  2. Finsterer J. Mitochondriopathies. Eur J Neurol 2004;11:163-86. https://doi.org/10.1046/j.1351-5101.2003.00728.x
  3. Munnich A, Rotig A, Chretien D, Cormire V, Bourgeron T, Bonnefont JP, et al. Clinical presentation of mitochondrial disorders in childhood. J Inherited Metab Dis 1996;19:521-7. https://doi.org/10.1007/BF01799112
  4. Gillis L, Kaye E. Diagnosis and management of mitochondrial diseases. Pediatr Clin N Am 2002;49:203–19. https://doi.org/10.1016/S0031-3955(03)00115-9
  5. Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N, et al. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics 2007;120:1326-33. https://doi.org/10.1542/peds.2007-0391
  6. Bettinelli A, Tosetto C, Colussi G, Tommasini G, Edefonti A, Bianchetti MG. Electrocardiogram with prolonged QT interval in Gitelman disease. Kidney Int 2002;62:580-4. https://doi.org/10.1046/j.1523-1755.2002.00467.x
  7. Bondy CA, Ceniceros I, Van PL, Bakalov VK, Rosing DR. Prolonged rate-corrected QT interval and other electrocardiogram abnormalities in girls with Turner syndrome. Pediatrics 2006;118:e1220-5. https://doi.org/10.1542/peds.2006-0776
  8. Baumgartner D, Scholl-Bürgi S, Sass JO, Sperl W, Schweigmann U, Stein JI, et al. Prolonged QTc intervals and decreased left ventricular contractility in patients with propionic acidemia. J Pediatr 2007;150:192-7. https://doi.org/10.1016/j.jpeds.2006.11.043
  9. Giunti S, Bruno G, Lillaz E, Gruden G, Lolli V, Chaturvedi N, et al. Incidence and risk factors of prolonged QTc interval in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2007;30:2057-63. https://doi.org/10.2337/dc07-0063
  10. Soliman OI, van der Beek NA, van Doorn PA, Vletter WB, Nemes A, Van Dalen BM, et al. Cardiac involvement in adults with Pompe disease. J Intern Med 2008;264:333-9. https://doi.org/10.1111/j.1365-2796.2008.01966.x
  11. Lev D, Nissenkorn A, Leshinsky-Silver E, Sadeh M, Zeharia A, Garty BZ, et al. Clinical presentations of mitochondrial cardiomyopathies. Pediatr Cardiol 2004;25:443-50. https://doi.org/10.1007/s00246-003-0490-7
  12. Holmgren D, Wahlander H, Eriksson BO, Oldfors A, Holme E, Tulinius M. Cardiomyopathy in children with mitochondrial disease; clinical course and cardiological findings. Eur Heart J 2003;24:280-8.
  13. Finsterer J, Stollberger C, Blazek G, Kunafer M, Prager E. Cardiac involvement over 10 years in myotonic and Becker muscular dystrophy and mitochondrial disorder. Int J Cardiol 2007;119:176-84. https://doi.org/10.1016/j.ijcard.2006.07.121
  14. Finsterer J. Overview on visceral manifestations of mitochondrial disorders. Neth J Med 2006;64:61-71.
  15. Rustin P, Chretien D, Bourgeron T, Gerard B, Rötig A, Saudubray JM, et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994;228:35-51. https://doi.org/10.1016/0009-8981(94)90055-8
  16. Desai M, Li L, Desta Z, Malik M, Flockhart D. Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol 2003;55:511-7. https://doi.org/10.1046/j.1365-2125.2003.01791.x
  17. Piccirillo G, Magrì D, Matera S, Magnanti M, Torrini A, Pasquazzi E, et al. QT variability strongly predicts sudden cardiac death in asymptomatic subjects with mild or moderate left ventricular systolic dysfunction: a prospective study. Eur Heart J 2007;28:1344-50. https://doi.org/10.1093/eurheartj/ehl367
  18. Schouten EG, Dekker JM, Meppelink P, Kok FJ, Vandenbroucke JP, Pool J. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 1991;84:1516-23. https://doi.org/10.1161/01.CIR.84.4.1516
  19. van Noord C, Straus SM, Sturkenboom MC, Hofman A, Aarnoudse AJ, Bagnardi V, et al. Psycotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol 2009;29:9-15. https://doi.org/10.1097/JCP.0b013e318191c6a8
  20. Salles GF, Bloch KV, Cardoso CR. Mortality and predictors of mortality in a cohort of Brazilian type 2 diabetic patients. Diabetes Care 2004;27:1299-305. https://doi.org/10.2337/diacare.27.6.1299
  21. Okin PM, Devereux RB, Lee ET, Galloway JM, Howard BV. Electrocardiographic repolarization complexity and abnormality predict all-cause and cardiovascular mortality in diabetes: the strong heart study. Diabetes 2004;53:434-40. https://doi.org/10.2337/diabetes.53.2.434
  22. Ishikawa K, Kimura S, Kobayashi A, Sato T, Matsumoto H, Ujiie Y, et al. Increased reactive oxygen species and anti-oxidative response in mitochondrial cardiomyopathy. Circ J 2005;69:617-20. https://doi.org/10.1253/circj.69.617
  23. Bonnet D, de Lonlay P, Gautier I, Rustin P, Rotig A, Kachaner J, et al. Efficiency of metabolic screening in childhood cardiomyopathies. Eur Heart J 1998;19:790-3. https://doi.org/10.1053/euhj.1997.0818
  24. Skinner JR, Yang T, Purvis D, Chung SK, Roden DM, Rees MI. Coinheritance of long QT syndrome and Kearns-Sayre syndrome. Heart Rhythm 2007;4:1568-72. https://doi.org/10.1016/j.hrthm.2007.08.013
  25. Barrera-Ramirez CF, Barragan-Campos HM, Ilarraza H, Iturralde P, Avila-Casado MC, Oseguera J. Cardiac involvement in Kearns-Sayre syndrome. Rev Esp Cardiol 2005;58:443-6. https://doi.org/10.1157/13073899
  26. Bonnet D, Martin D, De Lonlay P, Villain E, Jouvet P, Rabier D, et al. Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation 1999;100:2248-53. https://doi.org/10.1161/01.CIR.100.22.2248
  27. Koizumi A, Nozaki J, Ohura T, Kayo T, Wada Y, Nezu J, et al. Genetic epidemiology of the carnitine transporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency. Hum Mol Genet 1999;8:2247-54. https://doi.org/10.1093/hmg/8.12.2247
  28. Kim JT, Lee YJ, Lee YM, Kang HC, Lee JS, Kim HD. Clinical characteristics of patients with non-specific and non-categorized mitochondrial diseases. Acta Paediatr 2009;98:1825-9. https://doi.org/10.1111/j.1651-2227.2009.01428.x
  29. Lee SM, Kim JH, Lee YM, Lee JS, Kim HD. Evaluation of renal function in children with mitochondrial respiratory chain complex defect: usefulness of cystatin C. Acta Paediatr 2009;98:1014-8. https://doi.org/10.1111/j.1651-2227.2009.01249.x
  30. Lee YM, Kang HC, Lee JS, Kim SH, Kim EY, Lee SK, et al. Mitochondrial respiratory chain defects: underlying etiology in various epileptic conditions. Epilepsia 2008;49:685-90. https://doi.org/10.1111/j.1528-1167.2007.01522.x

피인용 문헌

  1. Early cardiac evaluation in children with non‐specific mitochondrial disease with isolated mitochondrial respiratory chain complex I defect vol.48, pp.11, 2010, https://doi.org/10.1111/j.1440-1754.2012.02585.x
  2. Regain of visuospatial capacity after coenzyme Q10 in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke‐like episodes: a case report vol.24, pp.3, 2010, https://doi.org/10.1111/j.1601-5215.2011.00620.x
  3. Diagnosis and treatment of mitochondrial myopathies vol.45, pp.1, 2010, https://doi.org/10.3109/07853890.2011.605389
  4. Characteristic cardiac phenotypes are detected by cardiovascular magnetic resonance in patients with different clinical phenotypes and genotypes of mitochondrial myopathy vol.17, pp.None, 2015, https://doi.org/10.1186/s12968-015-0145-x
  5. Chronic maternal hypercortisolemia in late gestation alters fetal cardiac function at birth vol.314, pp.3, 2010, https://doi.org/10.1152/ajpregu.00296.2017
  6. Inhibition of aldose-reductase-2 by a benzofuroxane derivative bf-5m increases the expression of kcne1, kcnq1 in high glucose cultured H9c2 cardiac cells and sudden cardiac death vol.9, pp.25, 2010, https://doi.org/10.18632/oncotarget.23270
  7. Systematic review and meta-analysis of cardiac involvement in mitochondrial myopathy vol.5, pp.4, 2010, https://doi.org/10.1212/nxg.0000000000000339
  8. Cardiovascular Involvement in mtDNA Disease vol.18, pp.1, 2010, https://doi.org/10.1016/j.hfc.2021.07.003